A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients

Journal of Infectious Diseases

Volumn 192, Issue 7, 2005, Pages 1154-1157

  Humar, Atul ^a,b   Siegal, Deborah ^a   Moussa, George ^a   Kumar, Deepali ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG RESPONSE; DRUG SUBSTITUTION; FEMALE; HUMAN; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS CLEARANCE; VIRUS LOAD; VIRUS SHEDDING;

ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 25444432336     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/444398     Document Type: Article

References (10)

1. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611-20.
2. Cytomegalovirus. Am J Transplant 2004;4(Suppl 10):51-8.
3. Pescovitz MD, Rabkin J, Merion RM, et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44:2811-5.
4. Razonable RR, Paya CV. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004; 2:27-42.
5. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218-27.
6. Boivin G, Goyette N, Gilbert C, et al. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189:1615-8.
7. Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119-26.
8. Mattes FM, Hainsworth EG, Hassan-Walker AF, et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005; 191:89-92.
9. Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Antivir Ther 2005; 10:119-23.
10. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85-90.